IP Library Granted Patent US 12,508,325
Granted Patent B2
US 12,508,325 · App. 17/332,470 · Granted Dec 30, 2025

Compositions and methods for reprogramming diseased musculoskeletal cells

Inventors: Devina Walter (Columbus, OH); Shirley Tang (Groveport, OH); Judith Hoyland (Glossop, GB); Safdar Khan (Columbus, OH); Benjamin Walter (Columbus, OH); Daniel Gallego-Perez (Columbus, OH); Natalia Higuita-Castro (Columbus, OH)
Assignees: Ohio State Innovation Foundation; UMIP The University of Manchester Intellectual Property
A61K48/0025A61P21/00C07K14/4702C12N15/85C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,325
App. No.
17/332,470
Granted
Dec 30, 2025
Kind
B2
Abstract

Disclosed herein are compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo. In some embodiments, the disclosed method involves non-virally delivering intracellularly into the diseased musculoskeletal cells a polynucleotide comprising one or more nucleic acid sequences encoding one or more of the disclosed transcription factors.

Claims (9)

1 . A method for treating a musculoskeletal disease intervertebral disc (IVD) degeneration in a mammalian subject, comprising injecting into the IVD of the mammalian subject

(a) a first extracellular vesicle produced from a donor cell containing or expressing T-box family protein and a Forkhead-box (FOX) family protein;

(b) a second extracellular vesicle produced from a cell containing or expressing a Mohawk family protein and Scleraxis.

2 . The method of claim 1 , wherein the first extracellular vesicle is produced from a cell containing or expressing a T-box family protein, a SOX family protein, and a Forkhead box (FOX) FOX family protein.

3 . The method of claim 1 , wherein the first extracellular vesicle is produced from a cell comprising a polynucleotide comprising FOXF1, Brachyury, and Sox9 genes operably linked to an expression control sequence.

4 . The method of claim 3 , wherein the second extracellular vesicle is produced from a cell comprising a polynucleotide comprising Mohawk and Scleraxis genes operably linked to an expression control sequence.

5 . The method of claim 1 , wherein the T-box family protein is Brachyury.

6 . The method of claim 1 , wherein the donor cell is a musculoskeletal cell or skin cell.

7 . The method of claim 1 , wherein the donor cell is a nucleus pulposus (NP) cell, annulus fibrosis (AF) cell, cartilage endplate cell, articular chondrocyte, tenocyte, or osteoblast.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2022
From: WALTER, DEVINA; TANG, SHIRLEY; KHAN, SAFDAR; WALTER, BENJAMIN; GALLEGO-PEREZ, DANIEL; CASTRO, NATALIA HIGUITA
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 060815/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2022
From: HOLYLAND, JUDITH
To: UMIP THE UNIVERSITY OF MANCHESTER INTELLECTUAL PROPERTY
Reel/Frame 060815/0165 →
Continuity (2)
Provisional Application 62782734 · Dec 20, 2018
Related Publication 20220118109A1 · Apr 21, 2022
References Cited (15)
US 20070028314A1 · Komori · 2007 [cited by examiner]
US 20090076481A1 · Stegmann et al. · 2009 [cited by applicant]
US 20130230454A1 · Gardner · 2013 [cited by examiner]
US 20180273906A1 · Ashraf · 2018 [cited by applicant]
WO 2017167788A1 · 2017 [cited by applicant]
WO 2017211906A1 · 2017 [cited by applicant]
Zhu et al,Can extracellular vesicles be considered as a potential frontier in the treatment of intervertebral disc disease?, Ageing Research Reviews, 2023, pp. 1-17. [cited by examiner]
Oshchepkova, A.; Zenkova, M.; Vlassov, V. Extracellular Vesicles for Therapeutic Nucleic Acid Delivery: Loading Strategies and Challenges, 2023, pp. 1-34. [cited by examiner]
Xia et al, Biomaterials delivery strategies to repair degenerated intervertebral discs by regulating the inflammatory microenvironment, 2023, pp. 1-18. [cited by examiner]
National Academies of Sciences, Ch 5. Musculoskeletal Disorders, 2020, pp. 1-57. [cited by examiner]
Matta and Erwin, Injectable Biologics for the Treatment of Degenerative Disc Disease, Current Reviews in Musculoskeletal Medicine (2020) 13:680-687. [cited by examiner]
Distefano et al., Extracellular Vesicles as an Emerging Treatment Option for Intervertebral Disc Degeneration: Therapeutic otential, Translational Pathways, and Regulatory Considerations, Advanced Healthcare Materials, … [cited by examiner]
Tang et al, Nonviral Transfection With Brachyury Reprograms Human Intervertebral Disc Cells to a Pro-Anabolic Anti-Catabolic/Inflammatory Phenotype: A Proof of Concept Study, Journal of Orthopaedic Research, Nov. 2019, … [cited by examiner]
Czibik et al., Gene Therapy with Hypoxia-Inducible Factor 1 Alpha in Skeletal Muscle is Cardioprotective in Vivo, Life Sci., vol. 88, No. 11-12, 2011 [cited by applicant]
Merceron et al., Loss of HIF-1 Alpha in the Notochord Results in Cell Death and Complete Disapperance of the Nucleus Pulposus PLoS, vol. 9, No. 10, p. 1-11, 2014. [cited by applicant]